Author:
He Bin,Wahl Richard L.,Sgouros George,Du Yong,Jacene Heather,Kasecamp Wayne R.,Flinn Ian,Hammes Richard J.,Bianco Jay,Kahl Brad,Frey Eric C.
Reference25 articles.
1. A revolution in the treatment of non-Hodgkin's lymphoma;DeNardo;Cancer Biother. Radiopharm.,1998
2. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma;Knox;Clin. Cancer Res.,1996
3. IDEC-Y2B8 (Y-90 conjugated anti-CD20) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM);Wiseman;Blood,1997
4. Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma;Wiseman;Eur. J. Nucl. Med.,2000
5. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with Y90 -labeled anti-CD20 monoclonal antibody;Wagner;J. Nucl. Med.,2002
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献